This author has yet to write their bio.Meanwhile lets just say that we are proud BioSpace contributed a whooping 2923 entries.
In recent years, J&J has pumped hundreds of millions of dollars into its artificial intelligence (AI) capabilities, according to the WSJ, including bringing on some 6,000 data science and digital specialists and erecting a “cutting-edge” research facility in the San Francisco Bay Area, which it opened in September 2022.
The FDA granted accelerated approval to Eli Lilly’s reversible BTK inhibitor Jaypirca (pirtobrutinib) for the treatment of chronic lymphocytic leukemia or small lymphocytic leukemia in adult patients who have undergone at least two prior lines of therapy, including another BTK inhibitor and a BCL-2 inhibitor.
CEO Emma Walmsley projects that the British biopharma’s Arexvy sales will exceed £1 billion in its first year on the market, leaving Pfizer’s Abrysvo respiratory syncytial virus vaccine far behind in the race.
In May 2023, the menopause drug received FDA approval for treating moderate to severe symptoms. Astellas said in Thursday’s announcement that the late-stage results “will support health technology assessment and reimbursement dossiers throughout Europe.”
Patients treated with Altimmune’s investigational GLP-1/glucagon dual receptor agonist saw up to 15.6% weight loss, and nearly a third of those taking the highest dose lost at least 20% of their body weight.
The troubled Indian pharma company received its second FDA warning letter in months, which this time cited quality control and data integrity lapses at its manufacturing facility in Gujarat, India.
The regulator accepted Karuna Therapeutics’ NDA and set a PDUFA date of September 26, 2024. If approved, it would be the first new mechanism of action to treat schizophrenia in decades, the company contends.
Boehringer Ingelheim is striking a deal to leverage artificial intelligence for some of the hardest to treat cancers. Phenomic AI announced a collaboration agreement with the pharma giant Wednesday.
In our highly polarized time, the idea that prescription drugs in the U.S. are priced unfairly compared with other countries is a rare issue that draws support from both sides of the aisle.
Under the terms of the deal, Lilly will make an upfront payment and pledges up to $660 million in preclinical, clinical and commercial development milestones. The Japanese biotech will also be eligible for royalties on future sales of any pharmaceutical product that emerges from the partnership.
